Germany Indapamide Market Trends, Research Report, Growth, Opportunities, Forecast 2022-2028

 

Germany indapamide market is estimated to grow significantly at a CAGR of around 3.6% during the forecast period. Due to the massive population of CVD, CHD, stroke, and rise in the adoption of indapamide drugs, the market is projected to grow considerably during the forecast period in Germany. The country has a quality healthcare system coupled with the cohesive government policies, that are driving the market in the region. As per the Institute for Health Metrics and Evaluation, around 192,000 cases of strokes were registered in the country in 2017 with a slight increment from 2014. Ischemic stroke is the leading stroke among all others in the country. As per Stroke Alliance for Europe (SAFE), in 2017 the prevalence of stroke was around 527,000 which is around 338 per 100,000 people. These high number of strokes prevalence in the country further increases the demand for indapamide in the country as it is used as the preventive treatment of stroke.

A full report of Germany Indapamide Market is available at: https://www.omrglobal.com/industry-reports/germany-indapamide-market

Germany indapamide market is segmented on the basis of product and application. Based on product, the market is bifurcated into 1.25 mg and 2.5 mg. Among these, the market for 1.25 mg medicine held the significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/germany-indapamide-market

The companies which are contributing to the growth of the Germany indapamide market include Merck KGaA, Sanofi S.A., Mylan N.V., Laboratori Baldacci S.p.A., Sandoz International GmbH, Bioindustria L.I.M. S.p.A. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.

Germany Indapamide Market- Segmentation

By Product

·         1.25 MG

·         2.5 MG

By Application

·         High Blood Pressure

·         Heart Failure

·         Others

Company Profiles

·         Bioindustria L.I.M. S.p.A.

·         Grupo Azevedos

·         Krka Group

·         Laboratori Baldacci S.p.A.

·         Merck KGaA

·         Mylan N.V.

·         Sandoz International GmbH

·         Sanofi S.A.

·         Servier Group

·         Teva Pharmaceuticals Industries Ltd.

Reasons to Buying From us –

1.       We cover more than 15 major industries, further segmented into more than 90 sectors.

2.       More than 120 countries are for analysis.

3.       Over 100+ paid data sources mined for investigation.

4.       Our expert research analysts answer all your questions before and after purchasing your report.

 

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

 

Media Contact:

Contact Person: Mr. Anurag Tiwari

Email: anurag@omrglobal.com

Contact no: +91 780-304-0404

Company Name: Orion Market Research